Lung HeXeRT: Helium, Xenon MRI for NSCLC Patients (HeXeRT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01859650|
Recruitment Status : Recruiting
First Posted : May 22, 2013
Last Update Posted : May 5, 2017
The University of Sheffield is one of the leading centres in the world for basic and translational research with inhaled gas MRI, which provides lung images with unprecedented spatial and temporal resolution. Our previous work demonstrated that inhaled gas MRI can provide significant clinical information for lung cancer radiotherapy planning and post-treatment evaluation. Building upon this unique experience, a multidisciplinary team will conduct an inhaled gas and proton lung MRI study that will address two of the major clinical problems faced by lung cancer patients treated with radiotherapy.
- Normal lung tissue is often damaged by the curative radiation dose. The investigators hypothesise that regional ventilation-perfusion lung function imaging with inhaled gas and proton MRI before and after treatment will help to lower the risk of radiation-induced lung injury and help to detect such damage at an early stage.
- Identification of the extent of cancerous tissue is error-prone when planning treatment from CT images alone. The investigators hypothesise that advanced proton MRI techniques will improve the identification of tumour volume, which is critical to successfully targeting the radiation dose.
To achieve these goals, image acquisition and image processing methods will be tested with a study of 20 patients. Results from this study will make an important contribution to improving the treatment of lung disease which is one of the key research priorities of the NHS.
|Condition or disease||Intervention/treatment|
|NSCLC||Other: MR and CT imaging|
|Study Type :||Observational|
|Estimated Enrollment :||20 participants|
|Official Title:||Lung HeXeRT: Advanced Proton, Hyperpolarised 3-helium and 129-xenon Magnetic Resonance Imaging for Lung Cancer Radiotherapy Planning and Evaluation|
|Actual Study Start Date :||December 2014|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
|NSCLC patients undergoing RT||Other: MR and CT imaging|
- Percentage of ventilated lung measured using inhaled gas MRI [ Time Frame: Change between pre treatment (average 10 days before start of treatment) and at 3 months post treatment ]
- Lung tumour volume measured using proton MRI [ Time Frame: Change between pre-treatment (average 10 days before start of treatment) and at 3 months post treatment ]
- Percentage of ventilated lung measured using CT [ Time Frame: Change between pre-treatment (average of 10 days before start of treatment) and at 3 months post-treatment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01859650
|Contact: Matthew Q Hatton, FRCR, FRCPfirstname.lastname@example.org|
|Sheffield Teaching Hospitals||Recruiting|
|Sheffield, United Kingdom, S10 2SJ|
|Principal Investigator: Matthew Q Hatton, FRCR, FRCP|
|Principal Investigator:||Matthew Q Hatton, FRCR, FRCP||University of Sheffield|